taurochenodeoxycholic-acid has been researched along with Thromboembolism* in 2 studies
2 other study(ies) available for taurochenodeoxycholic-acid and Thromboembolism
| Article | Year |
|---|---|
Treatment of experimentally induced cerebral atherothromboembolism in an animal model with streptokinase and taurochenodeoxycholate.
In cerebral atherothromboembolic accidents it is essential to quickly remove both the thrombotic and cholesterol crystal vascular obstructions. In this study we induced cerebral atheroembolic infarction in adult male NZW rabbits. Post induction we treated groups of animals with saline, streptokinase (SK)-only, or streptokinase and taurochenodeoxycholate (TCDC). The tissues were fixed 24 hours later and the infarcts were then measured. No remarkable damage resulted from the agents' use in the cerebral vascular bed, or in the hepatic parenchyma. Both treatments produced a dramatic reduction in the area and perimeter measurements of the infarcts when compared to control-treated animals. Both SK treatments drastically reduced the sizes of induced infarcts. It is suggested that a combined thrombolytic/emulsification treatment may drastically reduce the extent and distribution of cerebral infarcts which result from cerebral atherothromboembolism. Topics: Animals; Chenodeoxycholic Acid; Disease Models, Animal; Intracranial Embolism and Thrombosis; Male; Rabbits; Streptokinase; Taurochenodeoxycholic Acid; Thromboembolism | 1988 |
Combined streptokinase and taurochenodeoxycholate action on experimentally induced atherothromboemboli. Chandler Tube Study.
Atheroembolic lesions consist of both thrombus and atheroma, including cholesterol crystals; therefore, dissolution requires both a thrombotic agent and a lipid emulsifier. In vitro tests were performed in a Chandler tube apparatus to assess the effectiveness of predetermined dose and concentration levels for such agents. Between 0.065 and 0.1 mL of human atheroma, concentrated at 125 mg/mL, was added to 1 mL of recalcified rabbit whole blood in a Chandler tube to produce an atherothromboembolus. Specified amounts of streptokinase (SK) and/or taurochenodeoxycholate (TCDC) were introduced into the tube, either SK first, followed 30 minutes later by TCDC, or in the reverse order. The experimental thrombi were measured for length and weight, and samples from representative thrombi were processed and examined with both light and transmission electron microscopy. The combined SK/TCDC treatment appears to work best of all the treatments in reducing the size of the experimental thrombi and their cholesterol crystal components; and better than the TCDC/SK treatment. It is suggested that this combined treatment might be useful in the treatment of atherothromboembolism. Topics: Animals; Arteriosclerosis; Chenodeoxycholic Acid; Drug Therapy, Combination; Rabbits; Streptokinase; Taurochenodeoxycholic Acid; Thromboembolism | 1986 |